Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
about
A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.Association between chemotherapy response and rate of disease progression in disseminated melanoma.Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathwayImidazoles as potential anticancer agents
P2860
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
@ast
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
@en
type
label
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
@ast
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
@en
prefLabel
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
@ast
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
@en
P2093
P2860
P356
P1476
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
@en
P2093
Alevizakos N
Athanassiou A
Bafaloukos D
Barbounis V
Dimitriadis M
Pectasides D
Varthalitis J
Yianniotis H
P2860
P2888
P304
P356
10.1038/BJC.1989.327
P407
P577
1989-10-01T00:00:00Z
P5875
P6179
1031662839